1000 Mylan Boulevard
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, Mylan innovates to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership
Founders: Milan Puskar, and Don Panoz
CEO: Heather Bresch
CFO: Neil Dimick
866 articles with Mylan
Global Pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the decision of the U.S. Patent Trial and Appeal Board (PTAB), which found that tribal sovereign immunity cannot apply to prevent inter partes review (IPR) proceedings.
AbbVie announced patent license agreements with Mylan over its proposed biosimilar adalimumab product.
AbbVie continues to do what it can to protect its Humira-driven revenue stream. This morning the company inked an agreement to grant Mylan the rights to begin marketing its biosimilar to Humira in the United States in 2023.
The U.S. Food and Drug Administration (FDA) was busy during the first half of this year with more than 20 novel drug approvals. Of those approvals, one-third came in June.
Mylan N.V. today announced the U.S. launch of Rivastigmine Transdermal System, 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, a generic version of Novartis' Exelon® Patch.
The U.S. Food and Drug Administration withdrew its draft guidance on statistical methods to evaluate the analytical similarity between branded drugs and biosimilars.
Adamis Pharmaceuticals is selling U.S. commercial rights to Symjepi, a competitor to Mylan’s EpiPen, to Novartis.
Through the partnership agreement, Mylan will commercialize Lupin's proposed etanercept biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most markets throughout Asia.
Not only are women generally underrepresented in the biopharma industry, but compared to many of the top male executives, underpaid. Here’s a closer look at the top five female executives by pay in the biopharma industry.
Bivalirudin for Injection is an anticoagulant intended for use with aspirin
6/15/2018Shares of Dr. Reddy’s Laboratories Ltd. are surging this morning after the FDA approved its generic version of Suboxone (buprenorphine and naloxone) sublingual film for opioid addiction.
In a brief statement, Mylan reported that the U.S. Food and Drug Administration (FDA) had informed the company that its Generic Advair Diskus had “minor deficiencies” that would be in a Complete Response Letter.
Award Presented at HDA Business and Leadership Conference
The U.S. Food and Drug Administration (FDA) approved Mylan’s Fulphila (pegfilgrastim-jmbd), a biosimilar to Amgen’s Neulasta (pegfilgrastim). The biosimilar was co-developed with Biocon.
U.S. FDA Approves Mylan and Biocon's Fulphila™ (pegfilgrastim-jmdb), the First Biosimilar to Neulasta®
Mylan N.V. and Biocon Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Mylan's Fulphila™ (pegfilgrastim-jmbd).
CEO Heather Bresch will present at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA, on Wednesday, June 13, 2018, at 1:20 p.m. PT / 4:20 p.m. ET.
Mylan and Biocon to Present New Data at the American Society of Clinical Oncology (ASCO) Annual Meeting Reinforcing the Efficacy, Safety and Immunogenicity of Ogivri™, the first biosimilar for Herceptin® approved by FDA
Mylan N.V. and Biocon Ltd. announced that 48-week results from the HERITAGE study will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter to Evolus for its Biologics License Application (BLA) for DWP-450 (prabotulinumtoxinA), a drug to treat frown lines similar to Allergan’s Botox.
Shares of Perrigo have yet to rebound following the company’s weekend announcement that it expects the U.S. Food and Drug Administration to issue a Complete Response Letter for its generic version of Teva’s ProAir asthma inhaler.
Total revenues of $2.68 billion, down 1% compared to the prior year period.